share_log

Morgan Stanley Downgrades Lyell Immunopharma to Equal-Weight, Lowers Price Target to $7

Benzinga Real-time News ·  Nov 14, 2022 06:22

Morgan Stanley analyst Matthew Harrison downgrades Lyell Immunopharma (NASDAQ:LYEL) from Overweight to Equal-Weight and lowers the price target from $15 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment